Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

H1-receptor antagonists: does a dose-response relationship exist?

F E Simons1

  • 1Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Canada.

Annals of Allergy
|December 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of antihistamines in the new millennium.

Postgraduate medicine·2009
Same author

Epinephrine for the out-of-hospital (first-aid) treatment of anaphylaxis in infants: is the ampule/syringe/needle method practical?

The Journal of allergy and clinical immunology·2001
Same author

Socioeconomic status, drug insurance benefits, and new prescriptions for inhaled corticosteroids in schoolchildren with asthma.

Archives of pediatrics & adolescent medicine·2001
Same author

Expression, purification, characterization and clinical relevance of rAed a 1--a 68-kDa recombinant mosquito Aedes aegypti salivary allergen.

International immunology·2001
Same author

Epinephrine absorption in adults: intramuscular versus subcutaneous injection.

The Journal of allergy and clinical immunology·2001
Same author

Income-based drug benefit policy: impact on receipt of inhaled corticosteroid prescriptions by Manitoba children with asthma.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2001
Same journal

Hay fever; a review of the literature for 1945.

Annals of allergy·2010
Same journal

Nasal and sputum smears.

Annals of allergy·2010
Same journal

Determination of penicillin-susceptible strains of bacteria.

Annals of allergy·2010
Same journal

Fleabite reactions; clinical and experimental observations and effect of histamine-azoprotein therapy.

Annals of allergy·2010
Same journal

D.H.E. 45 (dihydroergotamine) in the treatment of allergic megraine.

Annals of allergy·2010
Same journal

Antigenicity of proteins in relation to allergy.

Annals of allergy·2010
See all related articles

Second-generation H1-antagonists show a dose-dependent effect on histamine skin suppression. Recommended doses are optimal for safety and efficacy in allergic conditions.

Area of Science:

  • Pharmacology
  • Dermatology
  • Allergy and Immunology

Background:

  • Histamine receptor blockade is crucial for managing allergic reactions.
  • Limited dose-response data exists for H1-antagonists in allergic rhinitis and chronic urticaria.
  • Understanding optimal dosing is key for balancing efficacy and safety.

Purpose of the Study:

  • To investigate the dose-response relationship of histamine receptor blockade in skin.
  • To evaluate the efficacy and safety of H1-antagonist dosing in allergic conditions.

Main Methods:

  • Dose-response studies utilizing histamine-induced wheal and flare suppression in the skin.
  • Analysis of results from second-generation H1-antagonists.

Main Results:

Related Experiment Videos

  • Second-generation H1-antagonists demonstrated a dose-dependent increase in histamine skin test suppression.
  • Manufacturer-recommended doses appear optimal for safety, with increased adverse effects at higher doses.
  • Higher doses do not guarantee complete symptom relief due to unopposed inflammatory mediators.

Conclusions:

  • Dose escalation of H1-antagonists may not improve outcomes and can increase risks.
  • Adherence to recommended dosing is advised for optimal safety and efficacy.
  • Complete symptom control may require addressing multiple inflammatory pathways beyond histamine.